Volume | 942,143 |
|
|||||
News | - | ||||||
Day High | 15.185 | Low High |
|||||
Day Low | 14.73 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Catalyst Pharmaceuticals Inc | CPRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
14.80 | 14.73 | 15.185 | 15.12 | 14.73 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
13,221 | 942,143 | $ 15.07 | $ 14,200,236 | - | 11.09 - 17.765 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:09 | 28 | $ 14.92 | USD |
Catalyst Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.78B | 117.86M | - | 398.2M | 71.41M | 0.61 | 24.95 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Catalyst Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CPRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 15.70 | 16.25 | 14.73 | 15.22 | 2,457,617 | -0.72 | -4.59% |
1 Month | 15.90 | 16.665 | 14.73 | 15.43 | 1,374,979 | -0.92 | -5.79% |
3 Months | 14.71 | 17.495 | 13.1161 | 15.30 | 1,362,884 | 0.27 | 1.84% |
6 Months | 12.56 | 17.495 | 11.89 | 14.74 | 1,412,462 | 2.42 | 19.27% |
1 Year | 16.43 | 17.765 | 11.09 | 14.00 | 1,474,749 | -1.45 | -8.83% |
3 Years | 4.58 | 22.11 | 4.43 | 12.39 | 1,619,436 | 10.40 | 227.07% |
5 Years | 5.41 | 22.11 | 2.235 | 8.66 | 1,771,513 | 9.57 | 176.89% |
Catalyst Pharmaceuticals Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |